^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HSK29116

    i
    Other names: HSK29116, HSK 29116, HSK-29116
    Associations

    News

    Trials
    Company:
    Haisco
    Drug class:
    BTK degrader
    Related drugs:
    Associations

    News

    Trials
    over1year
    Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies (AACR 2023)
    Exploratory analyses will evaluate the relationship between HSK29116 anti-tumor activity and BTK gene mutations, as well as BTK protein degradation effects of HSK29116 . Descriptive statistics will be used to summarize all data.
    Clinical • P1 data
    |
    BTK (Bruton Tyrosine Kinase)
    |
    BTK C481S • BTK mutation • BTK C481
    |
    HSK29116